LC-HRMS analysis of the antisense oligonucleotide Mipomersen (Kynamro®)

contributed by YMC | 03/16/2021

Antisense oligonucleotides (ASOs) have an outstanding therapeutic potential, since they are used for the therapy of genetic diseases. Due to the specific binding of an ASO to the complementary sequence of the RNA of a target protein its formation is suppressed. The ASO Mipomersen (commercially available as Kynamro^®) was developed to treat homozygous familial hypercholesterolemia by inhibiting the production of the low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) and therefore by reducing their concentration in blood. In this application note, Mipomersen is used as a model for the analysis of ASOs using LC-HRMS according to Y. Sun et al. [1]. They worked with an YMC-Triart C8 metal-free column which is an excellent choice for oligonucleotide analysis.

Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE!

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

Receive communication from The Cannabis Scientist I want to stay up to date with the Mass Spectrometry field I want to stay up to date with the Spectroscopy field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.